Affibody AB ("Affibody") today announced that the Trial Review Committee (TRC) has recommended to advance the Phase I clinical study with the Radioligand Therapy (RLT) candidate ABY-271 in ...

The company's innovative product pipeline and exclusive CanSEEK technology offer groundbreaking cancer treatments that address unmet clinical needs, positioning POINT for leadership in the biopharma ...

Interim results from a phase 3 trial supported the use of the radioligand therapy 177 Lu-DOTATATE (Lutathera) as first-line therapy to treat high-grade gastroenteropancreatic neuroendocrine tumors.

Please provide your email address to receive an email when new articles are posted on . The addition of a radioligand therapy to first-line treatment with long-acting octreotide prolonged PFS for ...

Median PFS improved by more than 1 year for patients who received radioligand therapy. ORR improved by more than 30% for patients who received radioligand therapy. Adding radioligand therapy to ...

In metastatic hormone-sensitive prostate cancer (mHSPC), adding the radioligand 177 Lu-PSMA-617 (Pluvicto) to androgen deprivation therapy (ADT) and chemotherapy more than doubled biochemical ...

Novartis' experimental Lu-PSMA-617 radioligand therapy has improved the survival of prostate cancer patients with a hard-to-treat form of the disease, the Swiss drugmaker said on Tuesday. ZURICH, ...

"North America accounts for the largest share of the global Radioligand Therapy (RLT) market in 2024, driven by its advanced healthcare infrastructure, high adoption of innovative oncology treatments, ...

Alicia Morgans, MD: Nuclear medicine specialists play a big role in particular as we talk about radiopharmaceuticals and radioligand therapies. Jeremie, can you talk about your role as a nuclear ...

The US Food and Drug Administration (FDA) has approved a new radioligand treatment for certain men with metastatic castration-resistant prostate cancer (mCRPC), as well as a new radioligand diagnostic ...

FILE PHOTO: The logo of Swiss drugmaker Novartis is pictured at the French company's headquarters in Rueil-Malmaison ZURICH (Reuters) - Novartis' experimental Lu-PSMA-617 radioligand therapy has ...